Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) may benefit from treatment with a nebulized long-acting bronchodilator. BROVANA enables patients to breathe better to obtain the dose of medication. BROVANA is taken only twice daily for the long-term maintenance treatment of bronchoconstriction (tightening of the airways) in patients with COPD, including chronic bronchitis and emphysema.
When patients with moderate to very severe COPD may benefit from nebulized therapy
BROVANA may be the right fit
Requires minimal PIFR1,2
12-hr bronchodilation, few daily troughs3
Minimal dexterity or hand/breath coordination required
Provides additional long-acting control when used with existing anticholinergic therapy4
Improved lung function within minutes5,6*Improvement defined as 15% increase in FEV.
Improved patient-reported overall COPD symptoms7
Proven safety profile, fewer exacerbations5,6,8
BROVANA is not indicated for the treatment of acute episodes of bronchospasm.
The five most common adverse events reported in patients taking BROVANA 15 mcg bid and occurring more frequently than in patients taking placebo were: pain (8% vs 5% for placebo), chest pain (7% vs 6% for placebo), back pain (6% vs 2% for placebo), diarrhea (6% vs 4% for placebo), and sinusitis (5% vs 4% for placebo).
BROVANA is covered under Medicare Part B (prior SABA use no longer required) and most managed care plans.